Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) EBITDA Margin (2020 - 2025)

Treace Medical Concepts' EBITDA Margin history spans 6 years, with the latest figure at 15.04% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 1418.0% year-over-year to 15.04%; the TTM value through Dec 2025 reached 27.75%, down 110.0%, while the annual FY2025 figure was 27.75%, 110.0% down from the prior year.
  • EBITDA Margin reached 15.04% in Q4 2025 per TMCI's latest filing, up from 32.37% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 0.87% in Q4 2024 to a low of 57.51% in Q2 2022.
  • Average EBITDA Margin over 5 years is 27.55%, with a median of 30.74% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: crashed -3790bps in 2022, then skyrocketed 2787bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 16.74% in 2021, then soared by 47bps to 8.92% in 2022, then dropped by -8bps to 9.6% in 2023, then soared by 91bps to 0.87% in 2024, then plummeted by -1637bps to 15.04% in 2025.
  • Per Business Quant, the three most recent readings for TMCI's EBITDA Margin are 15.04% (Q4 2025), 32.37% (Q3 2025), and 36.73% (Q2 2025).